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ABSTRACT 
 
Regenerative medicine is an exponentially growing field that aims to regenerate a lost 
function, cell type or tissue due to damage, ageing or disease. Currently, more than 30,000 
gene- and cell-based therapies have been or are being tested in clinical trials. Since the eye 
benefits from accessibility and a supposed to be immune privilege, many groups are 
exploring different strategies to treat diseases affecting this organ. Age-related macular 
degeneration (AMD), the leading cause of blindness in people aged over 65 years old, could 
be one of the first diseases treated with human pluripotent stem cells (hPSC)- derived 
therapies. This thesis has been focused on the development of a scalable, robust, defined and 
xeno-free protocol to differentiate hPSC into RPE-like cells, ensuring the safety of the 
obtained product through genomic, tumorigenicity and biodistribution studies. Finally, the 
differentiation of an in-house derived GMP-grade hESC line using a completely GMP-
compliant protocol, together with the validation of a set of in-process and Quality Control 
tests has allowed to engage in conversations with the regulatory authorities to bring these 
cells closer to near clinical trials, and ultimately to AMD patients.  
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1 INTRODUCTION 
 
1.1 REGENERATIVE MEDICINE 
Regenerative medicine has the potential to recover or replace cells, tissues or organs 
damaged by age, disease or trauma. For many years, the only option for such replacement 
relied on the availability of donated organs or tissues. The limited amount of suitable and 
compatible donors encouraged the search for alternative sources. The stem cells’ discovery, 
the advances in cell culture and differentiation, together with the refinement of the gene 
editing techniques have been crucial milestones to reach the broader spectrum of cell and 
gene therapies available nowadays.   
Since many are the cases that could benefit from a cell or gene therapy, many efforts 
are being put in the development of this products. Up to now, almost 30,000 cell-based 
therapies and over 700 gene-based therapies have been or are being tested in clinical trials, 
being 16 the current number of products already approved by the Food and Drug 
Administration (FDA) 1. 
 
1.1.1 GENE-BASED THERAPIES 
The gene-based therapies’ strategy is the introduction of genetic material into the cells 
to compensate abnormal genes or to express proteins that are beneficial for the treatment or 
prevention of a disease.  
The first approved and main application of the gene therapy is the generation of 
chimeric antigen receptor T-cells (CAR-T) 2. CAR-T cells are autologous T-cells that have 
been isolated and genetically modified to better recognise and kill haematopoietic cancerous 
cells once they are returned to the blood circulation. Nowadays, two CAR-T cell therapies are 
already in the market: Kymriah from Novartis to treat acute lymphoblastic leukaemia and B-
cell lymphoma 3,4, and Yescarta from Kite Pharma/Gilead to treat large B-cell lymphoma 5. 
Other gene therapies have been approved to treat prostate cancer 6, RPE65-mediated 
inherited retinal dystrophy 7, advanced melanoma 8 and coagulation disorders 9. 
Gene-based therapies have proved to be a valuable tool for the treatment of genetic 
diseases caused by specific mutations, but in some cases, only a few patients share the same 
exact mutation, being necessary the development of multiple gene therapies to treat the same 
disease. For instance, over 4,000 different mutations have been reported to cause retinitis 
pigmentosa (RP) 10. The extremely high cost of the development of these almost 
individualised therapies is not compatible with most of the companies’ business models so 
other alternatives and novel reimbursement models are being studied at the moment.  
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1.1.2 CELL-BASED THERAPIES 
On the other hand, cell-based therapies rely on the transplantation of healthy cells to 
replace the lost ones and/or to rescue the remaining ones by the secretion of growth factors 
and other beneficial molecules. Since the transplanted cells aim to recover the lost function 
without targeting a specific mutation, one single product would be sufficient to treat all the 
patients affected by the same disease even when presenting different mutations.  
Cell-based therapies can be divided in two big groups: autologous, when the used 
cells belong to the patient 11–16, and allogeneic, when the cells come from a different donor 17–
21. In principle, an autologous therapy would be immune-tolerated by the patient, while an 
allogeneic one would require immunosuppression to avoid the rejection of the foreign 
transplanted cells. Unfortunately, in most of the cases, the patient’s cells are not available or 
functional, being the allogeneic therapy the only option. In these cases, human leukocyte 
antigens (HLA)-matching will always be preferable. Currently, gene editing techniques are 
being used to remove and introduce some of the HLA genes that would be recognised by the 
immune system, thus developing a universal cell that would be compatible with everyone 22–
28. 
The discovery of the stem cells by James Till and Ernest McCulloch in 1961 29,30 
highly contributed to the evolution of this revolutionary field. Stem cells have the capacity to 
divide, proliferate and differentiate into multiple lineages and cell types. Adult stem cells can 
be found and extracted from adult tissues like bone marrow, skin, muscle, intestine, adipose 
tissue and blood, and they are usually multipotent, already committed to a limited number of 
mature cell types. Fetal stem cells come from aborted fetus and they are also multipotent. On 
the other hand, human embryonic stem cells (hESC) and human induced pluripotent stem 
cells (hiPSC) are pluripotent (Fig. 1). Although adult and fetal stem cells have been and are 
being used in several clinical trials 31–34 (clinicaltrials.gov numbers NCT02464436 and 
NCT03073733), they have some limitations, and the fact that hESC and hiPSC are an 
unlimited source able to differentiate into any cell type, makes them the true gem of the 
regenerative medicine. 
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Figure 1. Schematic representation of main stem cell types used in regenerative medicine 
 
Nowadays, multiple cell types are being tested in clinical trials, and several cell-based 
products are already in the market 15–17,19,20,35 to treat cartilage defects, wounds of the oral soft 
tissue, wrinkles appearance or hematopoietic disorders. 
 
1.2 PLURIPOTENT STEM CELLS 
Stem cells are a cell type that remains in an undifferentiated state. In most of adult 
tissues remains a small population of adult stem cells that keep dividing and differentiating to 
ensure the proper turnover and function of the tissue 36–38. Nevertheless, these cells are 
unipotent or multipotent, meaning that they are already committed to generate one or few cell 
types of the tissue where they belong. Some therapies focus on the activation of these 
quiescent cells, already present in the tissue or organ 39,40, others on providing the right 
environment for these cells to repair and regenerate the damaged tissue 41. 
On the other hand, PSC have two main features that makes them a unique source for 
cell-based products. PSC have the capacity to self-renew, meaning that when kept in the right 
conditions they can proliferate remaining undifferentiated and conforming an unlimited 
source of young cells, but when exposed to specific conditions they can also differentiate into 
any cell type in the body. Although in the recent years, several groups have been exploring 
new cell types that claim to be totipotent 42–46, hESC and hiPSC are the main sources used in 
cell therapies.  
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Even though most of the PSC-derived products are fully differentiated cells, one 
possible concern inherent to the nature of these cells is the possibility of remaining 
undifferentiated cells in the final product. Since the transplantation of proliferating PSC could 
result in a tumor formation among other complications, exhaustive tests have to performed to 
completely rule out the possible presence of these cells.  
 
1.2.1 HUMAN EMBRYONIC STEM CELLS 
When James A. Thomson published in 1998 the first successful derivation of hESC, a 
very promising new source for cell therapies was presented 47. Since then, the immense 
potential of these cells has been greatly accepted by the scientific community and many are 
the groups that have been and still are exploring all their capabilities.  
hESC are derived from the inner cell mass of surplus blastocysts. When they are 
cultured in the presence of basic fibroblast growth factor (bFGF) and transforming growth 
factor (TGFbeta) they maintain their stemness: proliferating and remaining undifferentiated 
48. The removal of one of these components or both from the media results in cell 
differentiation towards different lineages 49,50, and the addition of growth factors or small 
molecules are also being used to direct the differentiation towards specific cell types 51,52, 
promoting a faster and more efficient process. 
Currently, multiple clinical trials are testing the potential of several hESC-derived 
products to treat diseases like age-related macular degeneration (AMD) 53–56, cardiac 
ischemia 57, type I diabetes (clinicaltrials.gov number NCT02239354, NCT03162926 and 
NCT03163511) or Parkinson’s disease (PD) 58,59.  
Although hESC lines are derived from in vitro fertilisation (IVF) surplus embryos that 
would have been discarded, the use of these lines has raised some ethical concerns in some 
society sectors. 
The allogeneic nature of hESC-derived products could be considered as another 
handicap of these cells. The possible mismatch in the HLA complex would require the use of 
immunosuppressive therapies, not always avoiding the possible immune rejection of the 
transplanted cells. Nowadays, there are on-going initiatives to generate hESC banks that 
would comprise a broader spectrum of HLA types, and larger percentages of the population 
could benefit from HLA-matched hESC-derived cells 60.  
These two main flaws of the hESC encouraged the search for an autologous 
alternative that would overcome rejection issues and possible ethical concerns. 
 
1.2.2 INDUCED HUMAN PLURIPOTENT STEM CELLS 
The discovery of iPSC by Shinya Yamanaka on 2006 represented a promising 
alternative to ESC: the introduction of few defined factors achieved the reprogramming of 
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somatic cells into an embryonic state-like 61. This pluripotent cell type would provide an 
autologous source that would overcome ethical issues and, theoretically, immune rejection 
problems. Although it has been extensively assumed that an autologous transplant would be 
immune-tolerated, some studies have shown that iPSC-derived cells could have an abnormal 
gene expression that would induce an immune response 62. The fact that hiPSC-derived cells 
would be individually generated for each patient makes this cell source highly expensive and 
time-consuming. Trying to overcome this drawback, as well as for hESC, hiPSC banks are 
being stablished 63–66. Nevertheless, recent studies have shown that in the absence of 
immunosuppression, HLA-matching alone is insufficient to grant long-term survival of 
transplanted grafts 67. 
Although hiPSC have had a shorter path than hESC, derivatives of these cells have 
also reached the patients to treat diseases like AMD 68, PD 69 and graft versus host disease 
(GvHD) (clinicaltrials.gov number NCT02923375). 
 
1.3 THE EYE 
The eye is the organ that provides the visual system. It is composed by many 
structures and its perimeter can be divided into three different layers (Fig. 2): 
- Sclera and cornea: the external layer 
- Iris, ciliary body and choroid: the intermediate layer 
- Retina: the internal layer 
 
Figure 2. Schematic structure of the eye 
 
The retina is a sensory layer that lines at the bottom of the eye, organized, at the same 
time, in several layers (Fig. 3). These layers contain different types of neurons that, after 
receiving the light stimuli focused by the cornea and the lens, will transduce chemical and 
electrical signals from the photoreceptors, situated at the bottom, all the way up to the 
ganglion cells, the optical nerve and to the brain, where the image will be finally generated. 
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Figure 3. Representation of the different layers of the retina at the fovea 
 
In the middle of the retina, there is a demarcated region called macula. This circular 
area is functionally and structurally different from the rest of the retina, and it is the presence 
of zeaxanthin and lutein what gives its characteristic “yellow” colour 70. The main function of 
these pigments, together with other mechanisms, is to protect and preserve the most essential 
structure of the retina for human vision, the fovea. This small valley located in the middle of 
the macula shows the highest cones’ density, providing colour discrimination and visual 
acuity (Fig. 4).  
 
Figure 4. Representation of the fundus of the eye circling the macula with the fovea (*) 
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1.3.1 PHOTORECEPTORS 
Cones and rods are two specialised types of neurons, globally known as 
photoreceptors, conforming the basal layer of the retina. These cells capture the light through 
structures called outer segments, posteriorly converted into chemical and electrical signals in 
the inner segments, and finally transduced to the rest of neuronal layers in the retina through 
synaptic connections, a phenomenon known as phototransduction 71.  
Rods are greater in number, thinner and more sensitive to lower amounts of photons, 
procuring vision under dark-dim conditions at night. Cones are scarcer and require brighter 
light to be stimulated. Depending on the absorbed wavelength, we can discriminate between 
red cones (long wavelength), green cones (medium wavelength) and blue cones (short 
wavelength), and the combination of these three provides colour perception 72 (Fig. 3). 
Seeing the important role that these cells play on the visual system, it is not surprising that 
their dysfunction or deficiency leads to many vision problems and eye diseases. For instance, 
mitochondrial DNA deletions in foveal cones have been correlated to several maculopathies 
73.   
 
1.3.2 RETINAL PIGMENT EPITHELIUM 
The Retinal Pigment Epithelium (RPE) is a compact monolayer of heavily pigmented 
hexagonal and polarized cells lying underneath the retina. The finger-like processes that 
emerge from its apical membrane are in direct contact with the photoreceptors, providing 
them nutrients like omega-3 fatty acids, amino acids and glucose, disposing their waste and 
recycling their outer segments through phagocytosis 74. In order to sustain the photoreceptors, 
its apical part also secrete growth factors like pigment epithelium-derived factor (PEDF), 
TGFbeta and platelet-derived growth factor (PDGF) 75,76. 
The RPE’s location enables this structure to perform as a blood-retinal barrier, 
another important function that prevents nonspecific diffusion of material from the choroid 
but favours the transport of other substances like water, ions, metabolic end products and 
vascular endothelial growth factor (VEGF) from the subretinal space to the choroid 77. It has 
been suggested that the secretion of immunosuppressive cytokines by the RPE cells would 
contribute to the immune privileged status of the eye 74,75,78, even though this statement is 
currently being reanalysed in the field. 
The presence of melanosomes in its cytoplasm absorbs any excess of incoming light, 
playing an important role on the protection of the retina from light damage. 
All these complex functions make the RPE a very essential structure to keep the 
homeostasis in the eye, and its disturbance can result in an abnormal visual function and 
develop into several eye diseases. 
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1.3.3 BRUCH’S MEMBRANE 
The Bruch’s membrane is a thin layer of connective tissue firmly attached to the basal 
site of the RPE, acting as a physical and biochemical barrier between the choroid and the 
RPE. This extracellular matrix rich in elastin, collagen and laminin 79,80 also provides 
physical support for RPE cell adhesion, migration and differentiation 81. Any modification in 
its structure or composition, which depends on age, genetics, environmental factors, and 
disease state, could alter its diffusion properties, affecting RPE’s and outer retina’s function. 
 
1.3.4 CHOROID 
The choroid is the main source of blood supply to the retina, providing 65-85% of its 
flow, and it is crucial for the maintenance of the outer retina, especially the photoreceptors. 
The blood circulates through the choriocapillaris: fenestrated vessels adjacent to the Bruch’s 
membrane with a polarized expression of VEGF receptor towards the retinal side 82. Since 
they provide 90% of the oxygen consumed by the photoreceptors in darkness, any disruption 
in the choroidal blood flow would be detrimental to these cells 83. 
 
1.4 RETINOPATHIES 
There are several diseases affecting the retina called retinopathies. Macular 
degeneration, retinitis pigmentosa (RP), diabetic eye disease, retinal detachment, 
retinoblastoma, macular pucker, macular hole and floaters are the most common ones. Since 
the retina is a crucial structure for the vision, this sense is affected in different ways by these 
diseases, and in advanced stages they may even cause blindness. 
 
1.4.1 RETINITIS PIGMENTOSA 
RP is a group of rare inherited retinal diseases that affects 1 in 4000 people. Common 
symptoms comprise difficulty seeing at night and gradual loss of peripheral vision due to the 
progressive degeneration of photoreceptor cells. Over 4000 different mutations distributed 
along nearly 70 different genes have been reported in RP patients 10. The heterogeneity 
presented by the disease adds another level of complexity to the development of a suitable 
therapy. Although some gene-replacement therapies are being explored for specific 
mutations, additional mutation-independent approaches are also being developed to slow 
down the retinal degeneration, embracing a broader percentage of affected people with one 
single product 84. The viral-mediated expression of anti-apoptotic factors and secretion of 
retinal neurotrophic factors would diminish the photoreceptor cell death. 
Cell-based therapies are also being explored at the moment in RP patients: autologous 
bone marrow-derived stem cells have shown promising results 85,86 (clinicaltrials.gov number 
NCT02280135), and retinal progenitor cells are currently being tested in two on-going 
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clinical trials, using two different approaches. While one relies on the activation and rescue of 
endogenous remaining photoreceptors by the intravitreous injection of the progenitors 
(clinicaltrials.gov number NCT03073733), the other one relies on the replacement of lost 
photoreceptors by the subretinal injection of the cells (clinicaltrials.gov number 
NCT02464436). Although this last clinical trial has not been completed yet, some results 
have already been shared: while three patients showed a considerable visual acuity 
improvement, five patients reported almost no gain, and two of them even experienced a 
decline. These inconsistent results suggest that optimal patient selection and surgical 
procedure standardisation for future studies design is essential 87. 
 
1.4.2 STARGARDT’S DISEASE 
Stargardt’s disease is a genetic eye disorder and is one of the most common forms of 
macular degeneration in juvenile patients. The abnormal accumulation of the yellow pigment 
lipofuscin promotes photoreceptors’ death and the progressive vision loss from the macula. 
Although there is no treatment for Stargardt’s disease, several strategies are currently under 
study. One approach is to reduce the build-up of lipofuscin and other toxic byproducts in the 
retina by the administration of a synthetic form of vitamin A. Another approach would be the 
repair or replacement of ABCA4 gene, one of the most common mutated genes in these 
patients, also aiming to reduce the amount of accumulated lipofuscin88. Finally, cell-based 
therapies to rescue or to replace the damaged cells are also being tested in clinical trials55,56. 
 
1.4.3 AGE-RELATED MACULAR DEGENERATION 
AMD is the leading cause of blindness in industrialized countries in people over 65 
years old 89. Today, 8% of the world’s population is affected by this disease, and the 
projected number for 2020 is around 196 million, reaching to 288 million by 2040 90. 
Even though the exact causes underlying the disease are still unclear, it is known that 
demographic, cardiovascular, dietary and medication factors play an important role on the 
development and progression of the disease 91. For instance, the prevalence of AMD in 
female or white populations seems to be higher, although some studies revealed no sex 
differences in AMD risk 92 and the racial differences in the prevalence might be explained by 
factors other than pigmentation. On the other hand, smoking and hypertension would be 
lifestyle-related factors also associated with an increased risk of developing the disease 93.  
Apart from environmental factors, the manifestation of AMD also has an important 
genetic component. Among others, several polymorphisms in genes encoding proteins 
involved in immune regulation, like the complement, have been related to the disease’s 
development 94.  
AMD is a degenerative disease that affects several structures in the eye like the outer 
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neural retina, the retinal pigment epithelium, the Bruch’s membrane and the choroid, starting 
primarily in the macula generating a small black dot in the middle of the visual field, and 
eventually expanding through the fundus of the eye eradicating any residual vision (Fig. 5). 
Even though the disease presents defined hallmarks, depending on the presented 
pathogenesis, AMD has been extensively classified in two different types: exudative and non-
exudative.  
 
Figure 5. Scene looked through a healthy retina (left) and a diseased retina with AMD (right) 
Exudative AMD (a.k.a. neovascular or wet) is characterised by the proliferation of 
new blood vessels from the choroid, through the Bruch’s membrane and into the RPE layer, 
often causing subretinal haemorrhage (Fig. 6). It has been hypothesised that this vascular 
overgrowth could be a response of VEGF secretion from hypoxic RPE after a large vessel 
stenosis and choriocapillaris loss 95.   
 
Figure 6. Schematic drawings and fundus representing healthy and diseased retinas 
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On the other hand, non-exudative AMD (a.k.a. non-neovascular or dry) is 
characterised by a complex sequence: accumulation of Drusen deposits, hyperpigmented 
dysfunctional RPE cells, Drusen resorption and RPE, photoreceptor and choriocapillaris 
depletion, evolving most of the times in confluent areas of RPE death and photoreceptor 
atrophy, also known as geographic atrophy (GA) 96. It is this decrease in vessels’ lumen and 
density what would give the “dry” appearance to the disease. Even though Drusen deposits 
are one of the hallmarks of the disease, the presence of these accumulations of lipoproteins, 
immunoglobulin and complement complexes situated between Bruch’s membrane and RPE 
is not always correlated with AMD development 97–99. 
Although this classification is strongly settled in the field, the fine line separating 
these two types might disappear in the future as it has been shown that both of them can 
evolve into the other in more advanced stages 100. 
 
1.4.3.1 CURRENT APPROACHES TO TREAT AGE-RELATED MACULAR 
DEGENERATION  
Currently, treatments like anti-VEGF ocular injections are being used to stop the 
progression, and in some cases to restore the vision, of exudative AMD 101, which would 
imply only 10-15% of the total AMD cases. On the other hand, there is no stablished 
treatment for non-exudative AMD patients. Administration of supplements like zeaxanthin 
and lutein 102, complement pathway inhibitors, visual cycle inhibitors, intravitreal 
neurotrophic factors and lipid metabolism modulators are some of the prevailing procedures 
103, that far from curing the disease, would only delay the inevitable end point.  
Seeing the importance of RPE cells in the visual function, it seems plausible that the 
replacement of the lost cells could stop the disease and even restore vision. This idea has 
brought many experts to study several sources for the restoration. The transplant of 
autologous RPE cells from peripheral areas would be the least immunogenic option; 
nevertheless, since the cells come from the patient himself, they would most probably suffer a 
similar fate than the lost ones 11,104. Fetal RPE would be a healthier source but it is quite 
limited and its use would raise many ethical concerns 105. An unlimited and free from ethical 
discussions source would be the use of RPE cell lines 106, but some of them might show 
modified properties, not resembling mature native RPE cells.  
In the search for an unlimited, healthier, ethical and functional source, the discovery 
of hPSC opened many conceivable options 107. The fact that these young cells can be 
differentiated into any cell type in the body makes them a very valuable tool to treat a wide 
spectrum of degenerative diseases, AMD being among them 108,109. Nowadays, the use of 
hESC and hiPSC is being explored, both cell types presenting many advantages and 
drawbacks. Even though the use of autologous hiPSC, in principle, would not face rejection 
problems, it is still unclear the effect of the reprogramming mechanisms 110,111. Furthermore, 
the development of individualised therapies with today´s technology would imply an 
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enormous cost, both money and time wise. On the other hand, these handicaps would be 
defeated with the use of hESC: any possible reprogramming effect would be avoided, the 
costs would be considerably reduced and, with the arrangement of an immune matching 
hESC bank, rejection would be minimised. Nevertheless, since hESC are derived from 
human embryos, their use might face some ethical concerns. 
At the moment, different strategies are being developed to differentiate hESC into 
RPE cells. While some protocols rely on the aggregation of hESC into embryoid bodies 
(EBs) maintained in suspension, others are focused on differentiating an adherent 2D 
monolayer. On the first scenario, after some time in culture, small dark protuberances called 
optical vesicles (OV) emerge from the EBs, containing the pigmented RPE cells, whereas on 
the second case the cells are kept in culture until the appearance and maturation of RPE 
colonies. 
Using any of the previously mentioned strategies, it has been shown that a simple 
spontaneous differentiation is feasible removing bFGF from the culture media 112–114, 
although further purification processes would be required to enrich the obtained 
heterogeneous population, like manual dissection and enzymatic digestion of the OVs 
followed by its 2D culture, or manual selection and expansion of the RPE colonies. Aiming 
for a more efficient and directed differentiation towards RPE cells, some groups have 
developed other protocols that would demand the addition of several factors and the use of 
biological or engineered substrates; shortening the differentiation protocol and getting a more 
pure product 115–118.  
After differentiation, the obtained hESC-RPE cells have to be fully characterised. 
Their identity can be confirmed by scrutinising several features: hexagonal morphology, 
presence of pigmentation, expression of specific RPE markers like retinal pigment 
epithelium-specific protein 65kDa (RPE65), bestrophin1 (BEST-1) and microphthalmia-
associated transcription factor (MITF), and epithelial barrier integrity measured by trans 
epithelial electric resistance (TEER). Their functionality can be validated in vitro, by their 
ability to phagocyte photoreceptor outer segments and to differentially secrete VEGF and 
PEDF towards the basal and apical sides, respectively; and in vivo, by their capacity to 
integrate, survive and, in the best scenario, rescue visual function after their transplantation 
into animal models. Last but not least, before these cells can be considered as a therapeutic 
candidate, their purity has to be assessed using several tests, which will be explained in 
coming points. 
Trying to meet the highest possible levels in purity and to produce clinically 
compliant cells, many efforts are being done to develop xeno-free and defined protocols 119–
121. Avoiding the use of non-human components and working only with chemically-defined 
substances would highly reduce possible contaminants on the final product, decrease the risk 
of rejection after transplantation, obtain greater homogeneity between batches, and meet the 
requirements to produce the cells under good manufacturing practice (GMP) conditions, 
something increasingly demanded by the regulatory authorities when it comes to cell 
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therapies.  
Regarding to the therapy’s delivery into the subretinal space, different methods are 
being considered, and the use of animal models is a very convenient tool to determine the 
best approach before moving forward to the patients. Nowadays, one can choose among a 
wide variety of retinal degeneration models 122, being the Royal College of Surgeons (RCS) 
rat one of the most used 114,123,124. Nevertheless, the use of bigger animals like rabbits or 
primates would be preferable since it resembles more the human eye in several aspects 118,125. 
Currently, the field is independently exploring two different techniques to identify 
which would fit better the diverse clinical scenarios: a) subretinal injections of a cell 
suspension 115,126,127 and b) transplant of 2D sheets on scaffolds of different nature 118,124,128. 
The subretinal injection would be an easier procedure with minimal invasion covering bigger 
areas of cell loss but it relies on the inherent capacity of the cells to establish a monolayer on 
the subretinal space, whereas the transplant of the 2D sheet would require a more complex 
and invasive surgery, increasing the risk of damage on the retina’s structure and subsequent 
complications. Nevertheless, since the 2D sheets are mounted on protein-based or polymer-
derived scaffolds, their use might be more convenient in advanced stages of the disease where 
the Bruch’s membrane’s integrity is highly compromised. 
After seeing the positive outcome of the first clinical trial with hESC-RPE cells 
delivered as a cell suspension 55,56, several laboratories started looking into the refinement of 
this technique. For instance, hyaluronan-methylcellulose (HAMC) hydrogel used as an 
injectable scaffold is showing promising results 129. It would improve cell survival and 
quickly biodegrade after transplantation, overcoming some of the drawbacks observed with 
other substances like hyaluronic acid-based gels 130. 
 
1.5 SAFETY OF STEM CELLS THERAPIES 
In the development of any cell therapy that could be considered for transplantation to 
patients, reaching a product free from non-human components, containing only defined 
substances, is very important, but when it comes to cell therapies derived from stem cells it is 
also crucial to ensure their purity and safety.  
Stem cells possess the inherited properties of pluripotency and proliferation at 
considerably high rates, so the presence of residual undifferentiated cells in the final product 
could lead to undesired consequences. 
As the regenerative medicine field is moving forward, more groups are facing these 
challenges and, even though there are no standardised routines to follow, some authors have 
led the path suggesting several tests. The presence of undifferentiated cells could be checked 
in vitro, at a protein or RNA level by flow cytometry, immunostaining or qPCR, and in vivo 
by tumorigenicity and biodistribution tests 131,132. According to the International Stem Cell 
Initiative, the best method to prove pluripotency is the tumour formation upon the injection of 
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stem cells under mice’s skin 133,134. Several groups have used this assertion to test the lack of 
migratory and/or undifferentiated cells in their derived products 55,123,135,136 following the 
most relevant guidelines for this type of application: “Recommendations for the evaluation of 
animal cell cultures as substrates for the manufacture of biological medicinal products and for 
the characterization of cell banks” from the World Health Organization 137. 
Apart from discarding the presence of proliferative cells in the product, it is also 
necessary to check the genetic stability of the cells. Several studies have shown that the 
reprogramming methods and/or keeping the cells in culture for long time could introduce 
mutations in the DNA 68,138–142. Since some of the acquired mutations could be harmful for 
the patient, genomic analysis like karyotyping, genotyping or even whole genome sequencing 
could be required.   
 
1.6 WEARABLE ANALYTICAL DEVICES 
The regenerative medicine is an exponentially growing field that is generating many 
tools to treat diseases uncurable until now. As people’s lifespan is expanding, there is an 
increasing interest to pursue a healthier lifestyle and reach certain ages with a better quality of 
life. Technological advances are allowing the expansion of another growing field like the 
wearable analytical devices. Such devices consist in the integration of different kind of 
sensors into conventional objects like sweat bands, contact lenses, epidermal patches, glasses 
or microneedle patches 143,144. These sensors would allow a real-time monitoring of 
physiological parameters that could be used for rapid diagnosis, preventive medicine or even 
sport proficiency 145.  
Currently, nanoscale devices like transdermal patches are being explored 146. Most of 
the microneedle-based devices detect glucose through an amperometric readout, but only two 
published devices would detect ions using potentiometric sensors 147,148. Since such devices 
would be in direct contact with skin cells and interstitial fluid, possible cytotoxic effects have 
to be tested previous to their use in humans.   
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2 AIMS 
 
The general aim of this thesis has been to develop a scalable, safe and GMP-
compatible hESC-derived RPE therapy to bring a treatment for AMD closer to the clinic.  
The specific aims of the five projects have been: 
I. To prove the safety of our hESC-derived RPE cells, in terms of genomic stability, 
and tumorigenicity and migration potential. 
 
II. To develop a chemically defined, xeno- and manual selection-free protocol to 
differentiate hESC into RPE-like cells, and the discovery of cell-surface markers 
to validate the differentiation efficiency.  
 
III. To optimize and translate the developed protocol to differentiate our GMP-grade 
hESC line using fully compliant GMP reagents and materials, defining a set of 
assays and thresholds to ensure a pure, safe and validated global clinical 
production. 
 
IV. To evaluate the cytotoxicity of materials used in wearable microneedle patches for 
intradermal potentiometric detection of potassium in interstitial fluid.  
 
V. To test possible cytotoxic effects of ionophore-based membranes used in on-body 
ion sensors.   
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3 MATERIALS AND METHODS 
 
3.1 CELL CULTURE 
3.1.1 hPSC CULTURE 
hESC and hiPSC lines (with ethical permit from the Regional Ethics board of 
Stockholm, EPN 2011:745-31/3) were maintained by clonal propagation under xeno-free and 
defined conditions on human recombinant laminin (hrLN) 521-coated plates, in NutriStem 
hPSC XF medium and hypoxia conditions according to the previously described method 149. 
 
3.1.2 hPSC-RPE DIFFERENTIATION (OLD PROTOCOL) 
hESC and hiPSC were cultured to confluence on hrLN-521 and manually scraped to 
generate EBs according to the previously described method 120. EBs were differentiated in 
suspension in NutriStem hPSC XF medium without bFGF and TGFbeta, and in normoxia 
conditions. After five-week differentiation, OVs were manually dissected from the EBs and 
enzymatically dissociated flushing through a 20G needle. Cells were strained and seeded onto 
freshly hrLN 521-coated dishes with NutriStem hESC XF medium without bFGF and 
TGFbeta, and maintained in 2D culture for 30 more days.  
 
3.1.3 hPSC-RPE DIFFERENTIATION (NEW PROTOCOL) 
hESC and hiPSC were seeded at different densities on hrLN 521 or 111 with 
NutriStem hPSC XF and rho-kinase inhibitor, and maintained in hypoxia conditions. 24 
hours later, the cells were moved to normoxia conditions, and fed with NutriStem hPSC XF 
medium without bFGF and TGFbeta. From day 4,5, 6, 7 or 8 after plating, Activin A was 
added to the medium. Cells were fed three times a week and kept for 19 or 30 days, adding 
Activin A to the medium up to day 10, 15, 19, 25 or 30. Monolayers were collected for 
analysis or enzymatically dissociated into single cells for further differentiation. In this latter 
case, the cells were strained and seeded onto freshly hrLN 521-coated plates at different 
densities, kept for 19, 22 or 30 more days as monolayer with NutriStem hPSC XF medium 
without bFGF, TGFbeta and Activin A.    
 
3.2 QUANTITATIVE POLYMERASE CHAIN REACTION (QPCR) 
Total RNA was isolated using the RNeasy Plus Mini Kit and treated with RNase-free 
DNase. Complementary DNA (cDNA) was synthesised using 1 µg of total RNA. TaqMan 
Real-Time PCR master Mix together with TaqMan probes for glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH), nanog homeobox (NANOG), POU Class 5 Homeobox 1 
(POU5F1), sex-determining region Y-box 9 protein (SOX9), paired box 6 (PAX6), BEST1, 
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RPE65, premelanosome protein (PMEL), paired box 3 (PAX3), MITF, tyrosinase (TYR), 
platelet-derived growth factor receptor beta (PDGFRB), tubulin beta 3 class III (TBB3), and 
microtubule associated protein 2 (MAP2) were used. Samples were subjected to real-time 
PCR amplification protocol on a StepOne™ real-time PCR System. Biological triplicates 
were performed for every condition and technical duplicates were carried out for each 
reaction. 
 
3.3 FLUORESCENCE-ACTIVATED CELL SORTING (FACS) 
hPSC-RPE samples were stained with BV421 Mouse Anti-Human CD140b, PE 
Mouse Anti-Human CD140b, BB515 Mouse Anti-Human CD56, Alexa Fluor 647 Mouse 
Anti-Human TRA-1-60, BV421 Mouse Anti-Human CD184, BV421 Mouse Anti-Human 
Disialoganglioside GD2, PECy7 Mouse Anti- Human CD184, BV605 Mouse Anti-Human 
Disialoganglioside GD2 and BV605 Mouse Anti-Human CD104 conjugated antibodies. 
Fluorescence minus one (FMO) controls were included for each condition to identify and 
gate negative and positive cells. Stained cells were analysed using a CytoFLEX flow 
cytometer equipped with 488 nm, 561 nm, 405 nm and 640 nm lasers. Analysis of the data 
was carried out using FlowJo v.10 software.  
Cell sorting was performed on hPSC-RPE cultures after 21 days or 30 days of 
differentiation. Cells were incubated with the mentioned conjugated antibodies. FMO 
controls were included for each condition to identify and gate negative and positive cells. 
Stained cells were then sorted using a BD FACS Aria Fusion Cell Sorter.  
Right after sorting, 70,000 cells were cytospinned onto glass slides. Slides were fixed 
with 4% methanol-free formaldehyde and stained by immunocytochemistry.  
 
3.4 ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) 
hPSC-RPE were cultured on Transwell membranes coated with hrLN 521. 
Supernatants from both the hPSC-RPE apical and basal sides (meaning upper and lower 
compartments of the transwell, respectively) were collected 60 hours after the medium was 
changed. PEDF secretion levels were measured in triplicates for each condition with 
commercially available human PEDF ELISA Kits after 60 days of culture. The optical 
density readings were measured using SpectraMax 250 Microplate Reader.  
 
3.5 TRANSEPITHELIAL ELECTRICAL RESISTANCE (TEER) 
TEER RPE cells plated on Transwell membranes was measured using the Millicell 
Electrical Resistance System volt-ohm meter. 60-day cultures were equilibrated outside the 
incubator at room temperature before the experiment. Measurements were performed in 
unchanged culture media in triplicate for each condition, at three different positions of each 
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well. Averages were used for further analysis. The background resistance was determined 
from a blank culture insert in the same media coated with the corresponding substrate but 
without cells, and subtracted from the respective experiment condition. 
 
3.6 PHAGOCYTOSIS ASSAY 
hPSC-RPE were cultured on Transwell membranes coated with hrLN 521 for 30 days 
after re-plating. Cells were incubated at 37°C or 4°C with fluorescein isothiocyanate (FITC)-
labelled porcine photoreceptor outer segments (POS). After incubation, cells were quenched 
with Trypan Blue Solution, fixed with 4% methanol-free formaldehyde and permeabilized 
with 0.3% Triton X-100. Rhodamine-phalloidin staining was used to visualize cell 
boundaries. Nuclei were stained with Hoechst 33342.  
Images were acquired with a Zeiss LSM710-NLO point scanning confocal 
microscope. Post-acquisition analysis of pictures was performed using IMARIS and POS 
quantifications were done with CellProfiler 2.1.1 software.  
 
3.7 IMMUNOCYTOCHEMISTRY (ICC) 
Protein expression of day 60 hPSC-RPE cells was assessed through 
immunofluorescence. Cells were fixed with 4% methanol-free formaldehyde, followed by 
permeabilization with 0.3% Triton X-100 and blocking with 4% fetal bovine serum (FBS) 
and 0.1% Tween-20. Primary antibodies against PAX6, NANOG, BEST-1, MITF, Zonula 
occludens-1 (ZO-1), cellular retinaldehyde-binding protein (CRALBP), PDGFRB (CD140b), 
C-X-C chemokine receptor type 4 (CXCR4 or CD184), Ganglioside GD2, Ki67 and caspase 
3 (CASP3) were incubated overnight followed by incubation with secondary antibodies: 
Alexa Fluor 647 donkey anti-rabbit IgG, Alexa Fluor 488 donkey anti-mouse IgG, donkey 
anti-mouse IgG1 Alexa Fluor 568 and donkey anti- mouse IgG2a Alexa Fluor 488. Nuclei 
were stained with Hoechst 33342. Images were acquired with Zeiss LSM710-NLO point 
scanning confocal microscope. Post-acquisition analysis of the pictures was performed using 
IMARIS and/or Fiji/ImageJ.  
 
3.8 KARYOTYPING  
After EBs dissociation, hESC-RPE cells were plated on wells coated with hrLN 521. 
At day 7 (when cells were still proliferative), Karyomax colcemid was added to the medium 
for 28h. Cells were enzymatically dissociated. After centrifugation, the cell pellet was 
resuspended with the remaining solution after pouring off the supernatant, and 0.4% KCl was 
added. After centrifugation, 3:1 methanol:acetic acid fixative was added to the resuspended 
pellet. This action was repeated twice. Samples were analysed at Labmedicin Skåne, 
Genetiska Kliniken, Skånes Universitetssjukhus in Lund. 
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3.9 GENOTYPING  
Genomic DNA (gDNA) was isolated using the QIAmp DNA Mini Kit and 250 ng 
gDNA were analysed for Copy Number Variations with Genome-Wide Human SNP Array 
6.0 at Bioinformatics and Expression Analysis core facility (Karolinska Institute, Stockholm). 
 
3.10 WHOLE-GENOME SEQUENCING ANALYSIS 
gDNA was sequenced with Ilumina HiSeq X, 30X coverage. Whole-genome paired-
end DNA sequencing reads of HS980 (p22), HS980 (p38) and hESC-RPE cells in biological 
triplicate experiments were aligned to the human reference genome using the Burrows-
Wheeler Aligner. Aligned binary alignment map (BAM) files were sorted using Picard. 
“GATK Best Practice” guidelines were followed to generate analysis-ready BAM files which 
includes local realignments and base quality recalibration using GATK bundle “b37” files 
that include data sets from HapMap, Omni, Mills Indels and 1000 Genome Indels databases. 
Additionally, single nucleotide polymorphisms (SNPs) from NCBI-dbSNP were included in 
the analysis.  
 
3.10.1 GERMLINE SINGLE NUCLEOTIDE VARIANTS  
Analysis-ready BAM files of HS980 (p22) were processed using GATK 3.7 
HaplotypeCaller walker in genomic variant call format (gVCF) mode with default 
parameters. Output gVCF files of individual HS980 (p22) replicates were used for raw single 
nucleotide variants (SNVs) identification using GenotypeGVCFs walker. Further, variant 
quality score recalibration (VQSR) was performed using VariantRecalibrator walker with 
default parameters followed by ApplyRecaliberation walker to select filter “PASS” variants 
separately for individual replicates. Finally, BCFtools “isec” utility was used to identify 
SNVs commonly present in all three replicates for further downstream analysis. As an 
additional control set for analysis, publicly available pre-processed germline SNVs from 11 
participants from personal genome project: UK were downloaded and annotated for clinical 
significance. 
 
3.10.2 SOMATIC SINGLE NUCLEOTIDE VARIANTS  
Somatic SNVs calling was performed using GATK 3.7-MuTect2 in a pair-wise 
manner with default parameters. Brief comparisons were made between HS980 (p22) and 
hESC-RPE, followed by HS980 (p22) compared with HS980 (p38) to find somatic SNVs. 
All analyses were performed for the three independent replicates.  dbSNP150 and COSMIC-
v83 VCF files were considered as an argument for dbSNP and COSMIC, respectively. In 
addition, filter “PASS” somatic SNVs identified as a final outcome of MuTect2 pairwise 
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analysis were merged to create a non-redundant set of somatic SNVs for HS980 (p22) vs 
hESC-RPE and HS980 (p22) vs HS980 (p38). 
 
3.10.3 COPY NUMBER VARIATIONS 
In the copy number variations (CNVs) discovery, both advanced microarray- and 
next-generation sequencing platform-based approaches were used to identify potential copy 
number changes during HS980 (p22) to hESC-RPE and HS980 (p22) to HS980 (p38) 
differentiation processes. gDNA of all samples were hybridized with the Genome-wide 
Human SNP Array 6.0. Affymetrix CEL files were imported to the Partek®Genomic Suite 6.6 
to perform pairwise CNVs analysis. Hybridization intensity signal for each hESC-RPE and 
HS980 (p38) samples were compared to HS980 (p22) control samples. The genomic 
segmentation algorithm (with the following parameters: minimum number of probes per 
segment = 10, p-value threshold ≤ 0.001, signal to noise ratio = 0.3 and diploid copy number 
range = 1.7 to 2.3) was used to identify loss and gain CNVs segments. Identified replicate-
wise CNVs segments were merged to create non-redundant CNVs segments for hESC-RPE 
and HS980 (p38) samples.  
Independently, BAM files were used to identify CNVs associated with hESC-RPE 
and HS980 (p38) compared to HS980 (p22) samples in a pairwise manner. The whole-
genome sequencing pipeline of CNVkit 0.9.3 tool with default parameters in “batch” mode 
was used to compare individual hESC-RPE and HS980 (p38) samples with respective HS980 
(p22) control samples. Copy number segments were identified using the circular binary 
segmentation (CBS) algorithm and annotated to genes using GRCh37 annotation from 
Ensembl-v75. Segments with log2 ratio ≥ 0.3 and ≤ 0.3 were classified as amplifications and 
deletions, respectively. Further, replicate-wise copy-number segments were merged to create 
non-redundant copy-number segments for hESC-RPE and HS980 (p38) samples. In-house 
Perl scripts were used to identify overlapping copy-number segments for hESC-RPE and 
HS980 (p38) samples. 
 
3.10.4 CLINICAL INTERPRETATIONS  
ANNOVAR utility tool integrated within UCSC Galaxy was used to functionally 
characterise all germline and somatic SNVs. To access clinical significance, clinically 
annotated SNVs from ClinVar databases and cancer specific coding mutations from 
COSMIC databases were downloaded. Further, overlapping study was performed with 
identified germline and somatic SNVs using BCFtools “isec” utility. Additionally, three 
separate lists of cancer-driver genes were prepared which include 723 genes from the 
COSMIC cancer gene census, 299 genes from Bailey MH et al., and 242 genes from the 
Shibata list. 
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3.11 SINGLE-CELL RNA SEQUENCING 
3.11.1 PROJECT I  
Mature hESC-RPE cells cultured for 5 weeks after dissociation from OVs and hESC 
passage 14 were enzymatically dissociated and strained. Cells were further stained with 
live/dead marker 7-AAD and live single cells were sorted into a 384-well plate in lysis buffer 
using the SORP BD FACSAria Fusion instrument. hESC-RPE were sorted in 338 wells and 
hESC in 46 wells; 2 wells were left empty. A validation plate with 30 wells containing hESC-
RPE (28 wells with single cells and 2 wells with 20 cells each) and two wells with lysis 
buffer only was run as control. Smart-Seq2 sequencing was carried out by the Eukaryotic 
Single Cell Genomics facility (ESCG, SciLifeLab, Stockholm, Sweden). 
For sequencing analysis, single cell transcriptome sequencing reads were mapped to 
the human genome (hg19) using STAR aligner. The number of reads for each RefSeq and 
Ensemble annotated genes were calculated using featureCounts. Cells were quality-filtered 
based on the exclusion criterium: have total aligned reads (within transcriptomic boundaries) 
lesser than 103 and have showed expression of fewer than 2,000 unique genes. Read count 
matrix from quality-filtered cells was processed using R package Seurat. Gene expression 
measurement was performed using NormalizeData function in Seurat with scale factor 
10,000 followed by log-transformation. RunPCA, JackStraw, FindClusters and RunTSNE 
functions were used to further process the data and obtain t-distributed stochastic neighbour 
embedding (t-SNE) cluster of cells. 
 
3.11.2 PROJECT II  
60 days hPSC-RPE cells were enzymatically dissociated and strained. Cells were 
transported to ESCG facility where a 3’ cDNA library was prepared for single cell RNA 
sequencing with the 10X Genomics platform. Cell Ranger 2.1.1 pipeline was used to convert 
Illumina base call files to fastq format, align sequencing reads to the hg19 transcriptome 
using the STAR aligner, and generate feature-barcode matrices. Cell Ranger quality-control 
filtered cells were analysed in R, using Seurat suite. As a further quality-control measure, 
RPE cells with 17 uniquely expressed genes (≥ 2,000 to ≤ 5,000), unique molecular 
identifiers (UMIs) (≥ 10,000 to ≤ 30,000) and percentage of UMIs mapping to mitochondrial 
(MT)-genes (≥ 0.025 to ≤ 0.10) were selected. Similarly, hESC cells with uniquely expressed 
genes (≥ 2,000 to ≤ 8,000), UMIs (≥ 10,000 to ≤ 80,000) and percentage of UMIs mapping to 
MT-genes (≥ 0.025 to ≤ 0.10). This filtration step resulted in final dataset of 616, 725, 779 
and 905 cells for CD140b+GD2-, CD140b+CD184-, re-plated 1:20 and hESC samples, 
respectively. Before, dimensionality reduction by principal-component analysis (PCA), cell-
cell variation in gene expression driven by UMIs, mitochondrial gene expression and cell-
cycle stages were regressed out during data scaling process. Variable genes within RPE 
samples were selected based on their normalized average expression and dispersion. For 
principal component (PC) selection, findings of PCHeatmap, jackStraw, PC standard 
deviations and Clustree analysis were assessed. The first 15 PCs were used for the t-SNE 
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projection and clustering analysis. Cell clusters were analysed by two approaches. Top 
differential genes were first identified for each cluster using Wilcoxon Rank Sum test. 
Secondary, signature gene expression (module scores) was computed for undifferentiated 
hESC and several cell types present in human retina. Cells expressing mesoderm markers 
were manually subdivided in a separate cluster using interactive plotting features of Seurat.  
 
3.12 HISTOLOGICAL ANALYSIS 
Mice teratomas were excised, fixed with 4% methanol-free formaldehyde and 
paraffin embedded. 4 μm tissue sections were processed further for haematoxylin-eosin (H-E) 
staining.  
Immediately after euthanasia, the rabbit eyes were enucleated and the bleb injection 
area was marked with green Tissue Marking Dye (TMD). An intravitreal injection of fixing 
solution (FS) and embedding in paraffin was performed. 4 μm serial sections were produced 
through the TMD-labelled area and stained with H-E.  
For immunostaining, slides were deparaffinised and put through antigen retrieval. 
Slides were blocked and incubated with primary antibodies against human nuclear mitotic 
apparatus protein (NuMA), BEST-1, CD140b/PDGFRB and CD56/neural cell adhesion 
molecule 1 (NCAM1), and secondary antibodies (Alexa Fluor 555 donkey anti-rabbit IgG 
and Alexa Fluor 647 donkey anti- mouse IgG). Sections were mounted with vector 
vectashield with DAPI mounting medium. For immunohistochemistry (IHC), slides were 
deparaffinised followed by antigen retrieval and stained for CD140b/PDGFRB and 
CD56/NCAM1. Images were taken with Olympus IX81 fluorescence inverted microscope. 
Post-acquisition analysis of the pictures was performed using ImageJ software.  
 
3.13 TUNEL ASSAY 
Apoptotic markers were analysed on tissue sections by Terminal deoxynucleotidyl 
transferase dUTP Nick End Labeling (TUNEL) assay. Images were taken with an Olympus 
IX81 inverted epifluorescence microscope. Post-acquisition analysis of the pictures was 
performed using the ImageJ software. 
 
3.14 ANIMALS 
After approval by the Northern Stockholm Animal Experimental Ethics Committee 
(DNR N56/15 and DNR N25/14), New Zealand white albino rabbits, aged 5 months and 
weighing 3.5 to 4.0 kg were used in these studies. All experiments were conducted in 
accordance with the Statement for the Use of Animals in Ophthalmic and Vision Research. 
After approval by the Southern Stockholm Animal Experimental Ethics Committee (DNR 
S14/15), CIEA NOG mice aged 4 weeks were used in these studies. 
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3.15 TUMORIGENICITY AND BIODISTRIBUTION STUDIES 
3.15.1 MICE 
hESC, EBs and hESC-RPE monolayers were enzymatically dissociated into single 
cell suspensions. Cells were counted, resuspended in medium to reach different 
concentrations and mixed with Matrigel Matrix. Matrigel cell suspensions were injected 
subcutaneously in NOG mice neck. A total of 90 NOG mice were injected, divided into 9 
groups of 10 mice each (6 groups with 10, 100, 1x103, 1x104, 1x105 or 1x106 hESC, 2 groups 
with 1x107 of 3- or 5-week EBs and 1 group with 1x107 hESC-RPE cells. Teratomas’ growth 
was monitored weekly up to 4 weeks or 7 months. 7 months after subcutaneous injection of 
10 million hESC-RPE cells, the mice were euthanised, and the organs (lung, liver, spleen, 
kidneys, heart and gonads) and transplanted cells were independently collected. Each organ 
was homogenised and 3 aliquots were processed for RNA isolation.  
For hESC and hESC-RPE cell spiking, serial dilutions of cells (ranging from 1 to 
1x106 cells) were mixed with mouse tissue.  
Isolated RNA from all samples was analysed by qPCR using the SYBR green 
protocol and human ribosomal protein lateral stalk subunit p0 (RPLPO) primers. Calculation 
of the equation relating log (cell/mg tissue) with Ct value allowed the inference of the amount 
of cells/mg present in each of the analysed organs based on the obtained Ct values. 
 
3.15.2 RABBITS 
hESC-RPE monolayers were enzymatically dissociated into single cell suspensions. 
Cells were counted and resuspended in Dulbecco’s phosphate-buffered saline (DPBS). 
Animals were anesthetized and the pupils were dilated. Microsurgeries were performed on 
both eyes using a 2-port 25G transvitreal pars plana technique. Without infusion or prior 
vitrectomy, the cell suspension (equivalent to 50,000 cells) was subretinally injected with a 
syringe connected to a cannula through the upper temporal trocar. After instrument removal, 
a light pressure was applied to the self-sealing suture-less sclerotomies. Local 
immunosuppression with intravitreal triamcinolone was administered one week prior to the 
surgery. In animals kept for long-term evaluation, intravitreal triamcinolone was re-
administered every 3 months. 
After confirming absence of immune rejection and integration of the transplanted 
cells through spectral-domain optical coherence tomography (SD-OCT) at 1, 4, 12 weeks and 
12 months, the rabbits were euthanised and the organs (lung, liver, spleen, kidneys, heart, 
optic nerve and vitreous) were independently collected. Each organ was homogenised and 3 
aliquots were processed for RNA isolation.  
For hESC and hESC-RPE cell spiking, serial dilutions of cells (ranging from 10 to 
1x106 cells) were mixed with rabbit tissue.  
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3.16 SCANNING ELECTGRON MICROSCOPY (SEM) 
hPSC-RPE cells were cultured on Transwell membranes coated with hrLN 521 for 60 
days and fixed. The membranes were cut out, ethanol-dehydrated and critical-point-dried 
using carbon dioxide. Inserts were mounted on specimen stubs using carbon adhesive tabs 
and sputter coated with a thin layer of platinum. SEM images were acquired using an Ultra 
55 field emission scanning electron microscope at 3 kV and the SE2 detector.  
 
3.17 TRANSMISSION ELECTRON MICROSCOPY (TEM) 
hPSC-RPE cells were cultured on Transwell membranes coated with hrLN 521 for 60 
days and fixed. The membranes were cut out, put into thin strips and post-fixated in osmium 
tetroxide. The membrane strips were ethanol-dehydrated and finally flat embedded in LX-
112. Ultrathin sections (~50–60 nm) were prepared using a Leica EM UC7 and contrasted 
with uranyl acetate followed by lead citrate. TEM imaging was done on a Hitachi HT7700 
transmission electron microscope operated at 80 kV and digital images were acquired using a 
Veleta CCD camera.  
 
3.18 STATISTICAL ANALYSIS  
For statistical analyses, two-way ANOVA and posthoc multiple comparisons using 
Tukey test were performed.   
 
3.19 VIABILITY TESTS 
To test the possible cytotoxicity of the membranes used in ion-sensing devices 35,000 
human dermal fibroblasts (HDFs) were cultured in different wells for 72h before adding the 
different membranes and components to the wells, either directly floating in the medium or 
on top of a Transwell. After 96h of incubation with the membranes, the cells were counted 
with MOXI automated cell counter.  
 
3.20 PROLIFERATION TESTS 
35,000 HDFs were cultured in different plates for 72h before adding the different 
membranes and components to the wells. After 6, 24, 36, 48, 72 and 96h of incubation with 
the membranes, the cells were counted with MOXI automated cell counter. 
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3.21 ADHESION TESTS 
The membranes were drop-casted into the empty wells, followed by the seeding of 
35,000 HDFs per well cultured for 48h approximately. Then, the cells were fixed with 4% 
methanol-free formaldehyde to continue with the immunocytochemistry.  
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4 RESULTS AND DISCUSSION 
 
One of the main challenges that gene- and cell-based therapies are facing is the 
scalability of the process. There are many good protocols nowadays that unfortunately are 
only feasible at a research level, in some cases being able to generate enough product to cover 
the clinical trials’ demand. Some products that have proven efficacy in this stage, and have 
been even approved, have encountered problems when scaling-up the production to reach 
commercial amounts. For this reason, it is crucial to design a scalable manufacturing process 
from the beginning of the protocol’s development. 
In our lab, a protocol to differentiate hESC into RPE like-cells had been developed 
120. This protocol, as well as many others 150,151 relies on the spontaneous differentiation of 
the cells through EB’s formation, cultured in suspension. Five weeks later, pigmented OVs 
that have emerged from the EB’s are manually dissected and dissociated into single cells, that 
are plated and cultured on a monolayer for 30 more days until the cells reach maturation (Fig. 
7). Although this protocol generates a highly pure RPE population, it presents several 
drawbacks: feeding EB’s in suspension and manually dissecting OVs is highly time 
consuming, the spontaneous differentiation results in batch-to-batch dependent efficiency, 
and the low ratio between the obtained RPE-like cells and the starting hESC could be highly 
improved. 
 
Figure 7. Graphical summary of the old protocol to differentiate hESC into RPE-like cells 
 
In order to overcome the mentioned flaws, we have introduced several modifications 
developing a defined, scalable, robust, xeno- and manual selection-free protocol: instead of 
EB’s suspension, plated hESC are maintained on a 2D monolayer culture on hrLN 521 with 
Activin A addition from day 6. 30 days later, Activin A is discontinued, and the cells are re-
plated on fresh hrLN 521 and kept for 30 more days to reach maturation (Fig. 8). The fact 
that the cells are cultured from the beginning as a monolayer and that no manual dissection is 
needed generates a more streamlined and amenable to automatization process. Since at day 
30 the cells are re-plated in 1:20 dilution, there is a ~1,300-fold increase in the yield, allowing 
a huge expansion in the production. Activin A addition, as shown previously 115,152–154, 
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promotes a neuroectoderm fate, increasing the efficiency of the differentiation and reducing 
batch-to-batch variation. In fact, this new protocol has proven to efficiently differentiate 
several hESC and hiPSC lines, showing high reproducibility and robustness. 
 
 
Figure 8. Graphical summary of the new protocol to differentiate hESC into RPE-like cells 
 
Unlike other protocols, where multiple molecules like nicotinamide, taurine or 
triiodo-thyronin are added to induce an RPE fate 115,116,123,154, our protocol only relies on the 
addition of Activin A, which has shown to improve RPE differentiation efficiency from 
40% to 90%. The fact that Activin A is the only added compound, makes the translation to 
the future GMP production much easier. 
Since our lab was stablished by Professor Outi Hovatta, a pioneer in the derivation 
of hESC in Europe, the extensive knowledge and know-how on these cells is the reason 
behind choosing this source for our therapy. Nevertheless, other cells types have been and 
are being explored to treat AMD. Algvere et al. transplanted fetal RPE cells to dry and wet 
AMD patients without immunosuppression, concluding that the integrity of the blood-
retinal barrier is essential to avoid the rejection of an allogenic graft  155. Binder et al. and 
MacLaren et al. transplanted autologous temporal, nasal or extrafoveal RPE cells to treat 
foveal neovascularisation 11,156,157 resulting in transient improved visual acuity in some of 
the treated eyes, without recurrence of the neovascularisation. Autologous transplants of 
adult cells present less chances to be rejected, nevertheless, these cells could still manifest 
the underlaying disease following the same degenerative fate. hiPSC-RPE would generate 
another autologous source, and since these cells would be “younger”, could still be 
functional for many years 68,154. 
Currently, several clinical trials are testing different conformations of the 
transplanted cells. The first-in-human iPSC-derived therapy to reach clinical trials was the 
transplant of an RPE sheet to treat wet AMD 68. The advantage of transplanting the cells as 
a monolayer is that the cell-to-cell junctions and interactions are already stablished, which 
improves the survival rate of the transplanted cells as well as the maintenance of their 
polarity, a crucial feature in RPE function 128.  
Kashani et al. and da Cruz et al. also transplanted an already stablished monolayer, 
but in both cases, the RPE cells lay on a synthetic scaffold, made of parylene and polyester, 
respectively 128,151,158. Another option is the strategy used by Sharma et al., with a 
biodegradable substrate 154. In advanced stages of the disease, when the Bruch’s membrane 
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is highly compromised, the support of a platform could offer great benefits. Nevertheless, it 
is important to keep in mind that sheet transplantations require a purpose-built delivery tool 
and more complicated surgery procedures that can carry postoperative complications. 
On the other hand, cell suspension injections, like our approach and others 
55,123,150,159, involves a less invasive procedure, minimizing possible adverse events. 
Schwartz et al. were the first ones to prove the safety of hESC-RPE carrying out the first-
in-human clinical trial involving hESC-derived transplant tissue 55,56. Their positive results 
on AMD and Stargardts’s disease encouraged the multiple clinical trials running nowadays.  
Another advantage of cell suspension is the feasibility to cryopreserve the cells, 
banking them and having a ready “off-the-shelf” product. Although it is under 
development, RPE sheets do not tolerate well the current freeze/thaw methods.  
Cell suspensions also allow sorting the desired cells right before the transplantation. 
A positive/negative selection using RPE/hPSC (or any undesired cell type) markers could 
be implemented. In fact, we have validated an RPE cell-surface marker that could be used 
for that purpose: PDGFRbeta (a.k.a CD140b). The fact that RPE progenitors, and not 
hPSC, start expressing this protein, being kept by mature cells, allows its use to enrich the 
product in an automated manner, either in the middle of the protocol or at the end. 
Furthermore, the marker has also proved to be useful on the quantitative analysis of RPE 
purity, a very convenient application when developing in-process and QC tests for GMP-
manufacturing. Although Choudhary et al. presented CD59 as another RPE marker that 
could be used in the same manner, our data show that CD59 is also expressed by hPSC, not 
being able to discriminate between differentiated and undifferentiated cells 160. 
Exploring a positive/negative selection, we also identified two other markers that 
could be used to eliminate alternative lineages that appear during the differentiation 
process: CD184 (a.k.a. CXCR4) and GD2. Nevertheless, our single cell RNA sequencing 
data has shown that that this strategy would not be required to achieve a highly pure 
product since no undifferentiated cells have been found in the non-sorted samples, and it 
would only remove a small existing mesoderm contaminant (1.2% present without 
selection) and a portion of eye-field progenitors (from 11.3% to 3%), two lineages without 
apparent harmful effects.  
As shown by many clinical trials, stem cell-derived therapies, like the one studied in 
this thesis, have a great potential to rescue and/or to regenerate a lost function, cell type or 
tissue, in the best cases being able to cure diseases that could not be treated otherwise. 
Nevertheless, they also present some risks that cannot be underestimated and have to be 
minimised.  
Due to the inherent properties of hPSC, the source used in this kind of therapies, 
together with the culture and differentiation processes that these cells are exposed to, three 
undesired events have to be scrutinised in the final product: the presence of lingering 
undifferentiated and proliferative cells, the possible insertion of harmful mutations, and the 
migration to locations different than the intended ones.  
Up to date, several groups with hPSC-RPE cells already in clinical studies have 
performed some tests to prove the safety of their products 68,135,154,158,161,162. Their leadership, 
together with the World Health Organisation’s suggestions 137 have served us to put together 
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a broad panel of assays to evaluate the safety of our cells. The exhaustive genomic analyses, 
single cell RNA sequencing, tumorigenicity studies and biodistribution tests performed have 
enabled to address all the events mentioned above (Fig. 9).   
  
 
Figure 9. Graphical summary of safety studies addressed in Paper I 
 
Some studies have shown that cells exposed to extended culture conditions or 
differentiation processes may acquire mutations 140,163. Since the developed protocol entails 
60 days in culture, the acquisition of variations cannot be underestimated. To further assess if 
the possible mutations would be induced by the differentiation itself or by the time that the 
cells have been in culture, whole genome sequencing has been performed on the source cells 
(hESC p22), the differentiated cells (hESC-RPE) and undifferentiated cells that have been 
maintained in culture for a similar period of time (hESC p38).  
Interestingly, ~1,500 somatic SNVs have been found in both samples, hESC p38 and 
hESC-RPE, when compared to the source hESC p22. Also, when looking at CNVs or larger 
structural changes, similar numbers (~290 and ~20, respectively) have been found in both 
samples, with 70% of overlap. These findings suggest that the acquired mutations are mainly 
a consequence of the time in culture rather than the differentiation procedure, which also 
emphasise the general need for shorter protocols.  
A major concern is the possible harmful effect of the found variations. For instance, 
after treating one patient, the first-in-human trial using RPE cells derived from hiPSC was 
suspended due to the finding of three SNVs and three CNVs that where not present in the 
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patient’s fibroblasts 164. Although the mutated genes were not driver genes for tumor 
formation, one of the SNVs was listed in a database of cancer somatic mutations. Aligned 
with this approach, we have matched the found variations with several cancer-related 
mutations databases like COSMIC or ClinVar. Remarkably, from the mentioned ~1,500 
somatic SNVs, only 8 have been reported in COSMIC, and even more importantly, none of 
them or the larger structural changes are found in cancer-driver genes.  
Apart from the acquired mutations, it is also very important to pay attention to the 
already present variations on the source cells. When we have compared our hESC p22 with 
the reference genome, more than 4,300,000 germline SNVs have been identified. Fortunately, 
only between 18 and 35 of these SNVs have been reported in COSMIC, ClinVar or the 
Shibata list, being all of them common variants, and similar numbers have been found when 
analysing the genome of 11 people from Personal Genome Project UK. The fact that the 
existing germline variants load is higher than the acquired through in vitro culture or 
differentiation, and that our source cells and normal participants show comparable load of 
clinically relevant germline SNVs emphasise the importance to examine the genome integrity 
at a deeper level than just karyotype and the challenge to find mutations-free starting 
material.  
Although matching the variations with cancer-related databases is a legit strategy, the 
clinical relevance of the found mutations has to be analysed with further and more 
informative functional assays. 
To address the potential risks of the mutations, tumorigenicity and biodistribution 
studies have been performed. Fortunately, 7 months after the injection of 10 million hESC-
RPE cells in the neck of 10 mice, which supposes 100 times what a patient would receive, no 
tumor has been found. In the same line, when analysing the organs, no human cDNA has 
been found either, suggesting the lack of tumorigenic and migratory potential of the product. 
The rabbit experiments showed similar results, although small levels of human cDNA could 
be detected in the optic nerve and vitreous samples, most probably due to the sampling 
procedure or cells that refluxed into the vitreous after the transplantation.  
The fact that the injection of 1.000 hESC or less has not been able to generate any 
tumor in the mice suggests that a residing small amount of undifferentiated cells among the 
RPE-like cells would most probably not suppose a harm for the patient. Nevertheless, since 
there is no certainty on this matter, it is very important to ensure the purity of the final 
product. Our analysis of the single-cell RNA sequencing generated two completely separated 
clusters, characterised by the expression of hESC and RPE markers, respectively. And most 
importantly, all cells in the RPE samples showed high levels of RPE markers, while none of 
them expressed any undifferentiated ones. 
Another feature that has raised some concerns regarding the use of hESC as a source 
for regenerative therapies is the possibility of yolk sac’s formation. Historically, this structure 
has been related to malignancy properties of the cells. In the teratomas formed by the 
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injection of our undifferentiated hESC, derivatives from the three germ layers have been 
found, but some of them also showed yolk sac formations. After doing some research in the 
literature, we have found that these structures are not a rare event 134,165,166, and the fact that 
the mature product is not tumorigenic suggests that this assumption could be reanalysed.  
Until now, all the groups embarked on clinical studies with hPSC-derived products 
have had to figure out the required pre-clinical studies together with the pertinent authorities. 
Although there are some available guidelines 137,167, a thorough standardisation of the 
informative studies is crucial to ensure the safety and success of stem cells derived therapies.    
With the ultimate goal of this thesis in mind, which is to bring hESC-RPE cells closer 
to the clinic, having proved the safety of the product and developed a scalable and robust 
protocol, its translation into a GMP-compliant process is the natural next step. 
Testing suitable GMP-compliant reagents and materials to efficiently differentiate the 
cells, as well as arranging a set of in-process and quality control (QC) tests with defined 
thresholds to ensure the potency and purity of the final product (Fig. 10) has constituted the 
last part of this endeavour. 
As mentioned, many protocols around the world have been developed to differentiate 
hPSC into RPE cells, but only a few of them fully defined, xeno-free and meet all GMP 
requirements.  
One of the main advantages of our protocol, when compared to other available ones, 
is the reduced number of reagents and growth factors that are used, making a short list to be 
replaced. Our defined protocol mainly relies on the use of NutriStem hPSC XF medium 
without bFGF and TGFbeta to start a spontaneous differentiation, on hrLN 521 to support 
cell adhesion, and on Activin A to promote RPE fate. After arduous discussions between the 
medium manufacturer and the GMP facility, NutriStem hPSC XF medium has been 
approved, but the research-grade hrLN 521 and Activin A needed to be replaced. Fortunately, 
both GMP-friendly Activin A from R&D systems and hrLN 521 from Biolamina have 
reproduced results with similar efficiencies and purities on the differentiation of our GMP-
grade hESC line (KARO1). These achievements, combined with the scalable manual 
selection-free monolayer protocol, are a great value for the future clinical production. 
Trying to reduce some time and cost of goods on the manufacturing, different 
exposure windows to Activin A and different lengths of each part the protocol were tested. 
Interestingly, the optimal exposure time to Activin A seems to be line dependent, and re-
plating the cells at least 30 days after starting the differentiation seems to be necessary, most 
probably related to the exposure time to Activin A. Since this molecule has showed to 
maintain pluripotency 48,168–170, the optimization of Activin A exposure is not only required to 
increase the RPE yield but also to minimise the lingering undifferentiated cells. 
As mentioned, currently there are several groups running clinical trials with hPSC-
derived RPE. The increasing diversity in protocols, manufacturing sites and starting materials 
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raises the need for a unified criterion capable of ensuring a constant and border-cross 
product’s quality. Having a combination of molecular and functional tests with defined 
thresholds that fully characterise intermediate and differentiated cells from three hESC lines 
will enable a robust and validated global production, ensuring the cells’ potency and 
minimising batch-to-batch variation (Fig. 10).  
The previously mentioned identification of CD140b as an RPE marker has been an 
extremely valuable addition to this set of tests as it is able to quantitatively evaluate the 
differentiation efficiency at the middle and the end of the protocol. 
Aiming for cheaper, safer and more convenient “off-the-shelf” product, the viability 
of the cells in the presence of the cryopreservant has also been tested, and again, the effect 
seems to be line dependent. It is still unclear which degree of cell maturation is the best in 
terms of transplantation, survival and integration, so the fact that the freeze/thaw step is well 
tolerated, by both the intermediate and more mature stages, is indeed encouraging.  
 
Figure 10. Proposed threshold values for in-process and Quality Control tests for GMP-production 
of hPSC-derived RPE cells at day 30 and 60 of differentiation 
As important as it is to prove the safety of stem cell-derived therapies, it is also 
important to prove the safety of any device intended to be on-the body. With the evolution of 
the health care system, there is an increasing demand for wearable sensors with different 
applications 171, from ion-detection on the sweat for a personalised recovery to disease 
prevention. Some of these sensors are synthetic devices that lay on the skin 172–174, sometimes 
even penetrating several layers and being in direct contact with the cells and interstitial fluids 
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175–179. For instance, ion-selective electrodes, a type of sensor that has attracted increasing 
attention over the past years 180–182, might comprise an ion-selective membrane composed by 
polymers and plasticisers, an ion exchanger and an ionophore. A major concern is the 
possible cytotoxic effect of any of these compounds that could lead to multiple adverse 
effects.  
After doing some research on the available literature, we have realised that there is a 
lack of studies addressing the cytocompatibility of such compounds, especially with 
fibroblasts, one of the main cell types of the skin. Thus, the performed viability, proliferation 
and adhesion tests provide valuable information for the design and fabrication of future 
devices. 
The culture of HDFs in the presence of different membranes with different 
compositions for a specific period of time has allowed us to conclude that only potassium 
ionophore I (a.k.a. valinomycin) and ammonium ionophore I (a.k.a nonactin) are able to leach 
from the membrane to the media, having a cytotoxic effect, with a ~55% of cell viability 
compared to control conditions. Nevertheless, it cannot be discharged that other ionophores 
may also present cytotoxicity with longer exposures (> 96h) 
The time-course assays have suggested that, since the reduction in cell numbers starts 
from 36h, the leaching of the ionophores occurs between 24 and 36h of incubation. 
Furthermore, the leaching also seems to be dependent on the conformation of the membranes, 
being the membrane typically used in inner-filling solution electrode the one with the worst 
outcome, most probably due to the higher content of valinomycin. Although it has been 
hypothesised that different plasticisers could also have an effect on the leaching of the 
ionophores, our results have not shown differences big enough to stablish a general 
conclusion. 
Up to now, all the observed cytotoxic effects have been a result of the ionophores’ 
leaching into the media. Trying to mimic a more real scenario with the cells in direct contact 
with the membranes, adhesion tests have been performed. These tests have been able to 
evaluate two different possible events: the cytotoxicity due to the direct contact with 
compounds and the cells’ capacity to adhere and grow on the membranes. For instance, 
Miller et al. reported the need for a cell-resistant coating to inhibit macrophage adhesion to 
their developed microneedle 183, which could interfere in the electroanalytical performance. 
While no preferential growth on the membranes has been observed, the plasticiser FNDPE, 
apart from the already described toxic ionophores, has also shown a cytotoxic effect after 36h 
of exposure. 
In order to evaluate the possible mechanisms behind the reduction in cell numbers by 
the different conditions, immunostaining for Ki67 (proliferation marker) and CASP3 
(apoptosis marker) has been performed. The reduced number in Ki67+ cells and the lack of 
CASP3+ cells on the valinomycin and nonactin membranes suggests that these compounds 
act inhibiting the fibroblasts’ proliferation, emphasising their possible adverse effects on the 
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skin’s turnover. Further experiments would be required to rule out mechanisms of action for 
cell death different than apoptosis.  
Since mutacin, another potassium ionophore, presents similar potentiometric 
performances and does not present toxicity, it could be considered as a biocompatible 
alternative to valinomycin. 
All these results encourage a prompt cytotoxic evaluation of the available compounds 
on the early stages of any sensor design and development with an intended biomedical 
application. 
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5 CONCLUSIONS    
  
With the increasing numbers of stem cells-derived therapies reaching clinical studies, 
there is a striking need for robust and scalable protocols that are able to produce large 
amounts of fully characterised and safe cells. 
The work developed during this thesis has contributed to the development of a 
defined, scalable, robust, xeno- and manual selection-free protocol that has proven to 
efficiently differentiate several hPSC lines into highly pure RPE-like cells. The identification 
of the RPE marker CD140b has provided a very practical tool to enrich the final product in an 
automated manner if desired, and to quantitatively assess the differentiation efficiency.  
An exhaustive panel of genomic and functional assays have proved the safety of our 
derived RPE-like cells, characterised by a considerable genomic stability as well as the lack 
of tumorigenic and migratory potential. The compiled tests could be a reference for the 
needed standardisation of safety studies on the development of stem cells-derived products. 
The replacement of some reagents and materials has allowed to efficiently 
differentiate an in-house derived GMP-grade hESC into RPE-like cells, following a fully 
GMP-compliant protocol. This achievement combined with the validation of a set of in-
process and QC tests with defined thresholds is bringing these cells closer to the GMP-
production and the near clinical studies. 
The findings on the cytotoxicity assays performed on the components used on ion-
sensing devices increases the awareness about the need for implementing this kind of studies 
during the very first steps of any sensor development with an intended on-body application. 
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6 FUTURE PERSPECTIVES   
  
At a global level, many efforts are being done around the world to keep developing 
new gene- and cell-based therapies to cover unmet needs. Currently, 16 products have been 
already approved by the FDA, and with over 30,000 new compounds in clinical trials, many 
more approvals are expected. These coming novel therapies present many new safety, 
manufacturing and regulation challenges that will have to be quickly addressed. Furthermore, 
in order to reach the patients, since these products carry a very high production cost, 
alternative reimbursement models will have to be found.  
When it comes to AMD’s treatment, different approaches have been and are being 
tested currently in several clinical trials. The coming results will put some light on which is 
the best path to follow. 
At a closer level, our lab has already stablished a hESC line under GMP conditions, 
and it has proved to efficiently differentiate it towards RPE-like cells following a GMP-
compliant protocol. Since a list of in-process and QC tests has been already validated, the 
next step is to start manufacturing the cells in Vecura, a GMP facility part of the Karolinska 
Cell Therapy Center (Stockholm). In order to safely bring these cells to clinical trials, early 
conversations with the pertinent regulatory authorities have already been stablished. 
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